HLB “Resolves most of the problems with US approval of new liver cancer drugs”
⚡ Quick Summary
(Seoul = Yonhap News) Reporter Park Sang-hyun = HLB [028300] has resolved most of the recent problems in the US approval process for the liver cancer new drug 'Riboseranib'...
